Sintilimab for relapsed/refractory (r/r) extranodal NK/T cell lymphoma (ENKTL): Extended follow-up on the multicenter, single-arm phase II trail (ORIENT-4).

被引：0
|
作者：
Li, Jianyong
Tao, Rong
Fan, Lei
Song, Yongping
Hu, Yu
Zhang, Wei
Wang, Yafei
Xu, Linxinyu
Sun, Xing
Zhou, Hui
机构：
[1] Jiangsu Prov Hosp, Nanjing, Peoples R China
[2] Shanghai Jiao Tong Univ, Xinhua Hosp, Dept Hematol, Sch Med, Shanghai, Peoples R China
[3] Zhengzhou Univ, Affiliated Canc Hosp, Zhengzhou, Peoples R China
[4] Henan Canc Hosp, Zhengzhou, Peoples R China
[5] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Wuhan, Peoples R China
[6] Peking Union Med Coll Hosp, Beijing, Peoples R China
[7] Tianjin Med Univ, Canc Inst & Hosp, Tianjin, Peoples R China
[8] Innovent Biol Inc, Suzhou, Peoples R China
[9] Innovent Biol Inc, Shanghai, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8050
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Chidamide plus R-GDP for relapsed/refractory diffuse large B-cell lymphoma in patients ineligible for autologous transplantation: A prospective, single-arm, phase II study
    Chen, Guang-Liang
    Xue, Kai
    Zhang, Qunling
    Xia, Zu-guang
    Jin, Jia
    Li, Ran
    Liu, Yizhen
    Lv, Fangfang
    Hong, Xiaonan
    Li, Xiaoqiu
    Cao, Junning
    CANCER MEDICINE, 2024, 13 (16):
  • [32] Brentuximab Vedotin and Nivolumab for Relapsed or Refractory Classic Hodgkin Lymphoma: Long-Term Follow-up Results from the Single-Arm Phase 1/2 Study
    Moskowitz, Alison J.
    Advani, Ranjana H.
    Bartlett, Nancy L.
    Vose, Julie M.
    Ramchandren, Radhakrishnan
    Feldman, Tatyana A.
    LaCasce, Ann S.
    Christian, Beth A.
    Ansell, Stephen M.
    Moskowitz, Craig H.
    Brown, Lisa
    Taft, David
    Ansari, Sahar
    Zak, Daniel E.
    Sacchi, Mariana
    Manley, Thomas
    Herrera, Alex F.
    BLOOD, 2019, 134
  • [33] L-MIND: MOR208 COMBINED WITH LENALIDOMIDE (LEN) IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (R-R DLBCL)-A SINGLE-ARM PHASE II STUDY
    Maddocks, K.
    Gonzalez Barca, E.
    Jurczak, W.
    Liberati, A. M.
    Duell, J.
    Nagy, Z.
    Papaj-K, T.
    Andre, M.
    Kalakonda, N.
    Dreyling, M.
    Zinzani, P. L.
    Ambarkhane, S.
    Weirather, J.
    Salles, G.
    HAEMATOLOGICA, 2017, 102 : 174 - 174
  • [34] Loncastuximab tesirine in Chinese patients with relapsed or refractory diffuse large B-cell lymphoma: a multicenter, open-label, single-arm, phase II trial
    Lin, Ningjing
    Sun, Xiuhua
    Zhou, Hui
    Zou, Liqun
    Zhou, Keshu
    Liu, Lihong
    Yang, Haiyan
    Hu, Kai
    Cai, Qingqing
    Liu, Yao
    Jin, Jie
    Zhang, Liling
    Li, Wenyu
    Guo, Ye
    Yang, Wei
    Luo, Feng
    Wang, Zhenguang
    Zhu, Rong
    Yang, Lei
    Song, Dan
    Song, Yuqin
    Zhu, Jun
    HAEMATOLOGICA, 2025, 110 (03) : 683 - 692
  • [35] L-MIND: MOR208 combined with lenalidomide (LEN) in patients with relapsed or refractory diffuse large B-cell lymphoma (R-R DLBCL) - a single-arm phase II study
    Duell, J.
    Gonzalez Barca, E.
    Liberati, A. M.
    Salles, G.
    Gaidano, G.
    Jurczak, W.
    Nagy, Z.
    Papajlk, T.
    Andre, M.
    Zinzani, P. L.
    Kalakonda, N.
    Ambarkhane, S.
    Weirather, J.
    Maddocks, K.
    Dreyling, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 68 - 68
  • [36] SINGLE-AGENT MOR208 IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL): A SINGLE-ARM PHASE II STUDY
    Klisovic, R.
    Winderlich, M.
    Ambarkhane, S.
    Jabbour, E.
    HAEMATOLOGICA, 2017, 102 : 346 - 346
  • [37] Orelabrutinib Monotherapy in Patients with Relapsed or Refractory Waldenstrom's Macroglobulinemia in a Single-Arm, Multicenter, Open-Label, Phase 2 Study: Long Term Follow-up Results
    Cao, Xinxin
    Jin, Jie
    Cheng, Fu Cheng
    Yi, Shuhua
    Zhao, Weili
    Sun, Zimin
    Yang, Wei
    Li, Dengju
    Cui, Guohui
    Hu, Jianda
    Liu, Ting
    Song, Yongping
    Xu, Bing
    Zhu, Zunmin
    Xu, Wei
    Zhang, Mingzhi
    Li, Sichen
    Wang, Weige
    Zhao, Renbin
    Zhou, Daobin
    BLOOD, 2023, 142
  • [38] Safety and Efficacy of Mitoxantrone Hydrochloride Liposome in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma and Extranodal NK/TCell Lymphoma: A Prospective, Single-Arm, Open-Label, Multi-Center, Phase. Clinical Trial
    Gao, Yan
    Huang, Huiqiang
    Wang, Xiaoxiao
    Bai, Bing
    Huang, Yunhong
    Yang, Haiyan
    Zhang, QingYuan
    Li, Yufu
    Li, Yan
    Zhou, Min
    Yang, Runxiang
    Xu, Bing
    Liu, Lihong
    Yang, Yu
    Peng, Zhigang
    Yu, Ding
    Zhou, Hui
    Zhang, Rong Yan
    Zhang, Huilai
    Qi, Junyuan
    Xi, Yaming
    Xing, Xiaojing
    Wang, Zhao
    Jing, Hongmei
    Zhang, Xiaohong
    Ma, Liping
    Jin, Hongyan
    Yao, Hongxia
    Shuang, Yuerong
    Xia, Xuefang
    Xue, Jianfei
    Li, Chunlei
    BLOOD, 2020, 136
  • [39] Nivolumab in Patients (Pts) with Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL): Clinical Outcomes from Extended Follow-up of a Phase 1 Study (CA209-039)
    Ansell, Stephen
    Armand, Philippe
    Timmerman, John M.
    Shipp, Margaret A.
    Garelik, M. Brigid Bradley
    Zhu, Lili
    Lesokhin, Alexander M.
    BLOOD, 2015, 126 (23)
  • [40] An open-label, single-center, phase II, single-arm trial of camrelizumab combined with apatinib in patients with relapsed or refractory peripheral T-cell lymphoma
    Xie, Y.
    Mi, L.
    Zheng, W.
    Ping, L.
    Lin, N.
    Tu, M.
    Zhang, C.
    Ying, Z.
    Liu, W.
    Deng, L.
    Wu, M.
    Wang, X.
    Zhu, J.
    Song, Y.
    ANNALS OF ONCOLOGY, 2020, 31 : S652 - S652
12345